LUX-Lung: determining the best EGFR inhibitor in NSCLC?

Lancet Oncol. 2015 Feb;16(2):118-9. doi: 10.1016/S1470-2045(14)71196-9. Epub 2015 Jan 12.

Authors

Antonio Rossi¹, Massimo Di Maio²

Affiliations

¹ Division of Medical Oncology, SG Moscati Hospital, 83100-Avellino, Italy. Electronic address: [email protected].
² Department of Oncology, University of Turin, AOU San Luigi Gonzaga, Orbassano, Turin, Italy.

PMID: 25589190
DOI: 10.1016/S1470-2045(14)71196-9

No abstract available

Publication types

Comment

MeSH terms

Adenocarcinoma / drug therapy*
Afatinib
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
ErbB Receptors / genetics*
Female
Humans
Lung Neoplasms / drug therapy*
Male
Mutation / genetics*
Quinazolines / therapeutic use*

Substances

Quinazolines
Afatinib
EGFR protein, human
ErbB Receptors